| Title: |
Genetically proxied glucose-lowering drug target perturbation and risk of cancer: a Mendelian randomisation analysis |
| Authors: |
Yarmolinsky, J; Bouras, E; Constantinescu, A; Burrows, K; Bull, CJ; Vincent, EE; Martin, RM; Dimopoulou, O; Lewis, SJ; Moreno, V; Vujkovic, M; Chang, K-M; Voight, BF; Tsao, PS; Gunter, MJ; Hampe, J; Pellatt, AJ; Pharoah, PDP; Schoen, RE; Gallinger, S; Jenkins, MA; Pai, RK; consortium, PRACTICAL; Program, VA Million Veteran; Gill, D; Tsilidis, KK |
| Contributors: |
Neal, D |
| Publisher Information: |
Springer |
| Publication Year: |
2025 |
| Collection: |
Oxford University Research Archive (ORA) |
| Description: |
Aims/hypothesis: Epidemiological studies have generated conflicting findings on the relationship between glucose-lowering medication use and cancer risk. Naturally occurring variation in genes encoding glucose-lowering drug targets can be used to investigate the effect of their pharmacological perturbation on cancer risk.Methods: We developed genetic instruments for three glucose-lowering drug targets (peroxisome proliferator activated receptor γ [PPARG]; sulfonylurea receptor 1 [ATP binding cassette subfamily C member 8 (ABCC8)]; glucagon-like peptide 1 receptor [GLP1R]) using summary genetic association data from a genome-wide association study of type 2 diabetes in 148,726 cases and 965,732 controls in the Million Veteran Program. Genetic instruments were constructed using cis-acting genome-wide significant (p |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| DOI: |
10.1007/s00125-023-05925-4 |
| Availability: |
https://doi.org/10.1007/s00125-023-05925-4; https://ora.ox.ac.uk/objects/uuid:bf99e11f-b0b8-4809-8af3-ba3e08ae0340 |
| Rights: |
info:eu-repo/semantics/openAccess ; CC Attribution (CC BY) |
| Accession Number: |
edsbas.D145B9CA |
| Database: |
BASE |